{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:28:50Z","timestamp":1794050930102,"version":"4.8.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008590","name":"Dr. Ralph and Marian Falk Medical Research Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Memory CD8+ T cells populate non-lymphoid tissues (NLTs) following pathogen infection, but little is known about the establishment of endogenous tumor-specific tissue-resident memory T cells (T<jats:sub>RM<\/jats:sub>) during cancer immunotherapy. Using a transplantable mouse model of prostate carcinoma, here we report that tumor challenge leads to expansion of na\u00efve neoantigen-specific CD8+ T cells and formation of a small population of non-recirculating T<jats:sub>RM<\/jats:sub> in several NLTs. Primary tumor destruction by irreversible electroporation (IRE), followed by anti-CTLA-4 immune checkpoint inhibitor (ICI), promotes robust expansion of tumor-specific CD8+ T cells in blood, tumor, and NLTs. Parabiosis studies confirm that T<jats:sub>RM<\/jats:sub> establishment following dual therapy is associated with tumor remission in a subset of cases and protection from subsequent tumor challenge. Addition of anti-PD-1 following dual IRE\u2009+\u2009anti-CTLA-4 treatment blocks tumor growth in non-responsive cases. This work indicates that focal tumor destruction using IRE combined with ICI is a potent in situ tumor vaccination strategy that generates protective tumor-specific T<jats:sub>RM<\/jats:sub>.<\/jats:p>","DOI":"10.1038\/s41467-021-24132-6","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:06:11Z","timestamp":1624442771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-7722","authenticated-orcid":false,"given":"Brandon J.","family":"Burbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1208","authenticated-orcid":false,"given":"Stephen D.","family":"O\u2019Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8190-1067","authenticated-orcid":false,"given":"Qi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-209X","authenticated-orcid":false,"given":"Katharine M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-1851","authenticated-orcid":false,"given":"Joseph R.","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan R.","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1352","authenticated-orcid":false,"given":"Tami Jo L.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-3949","authenticated-orcid":false,"given":"Lalit. K.","family":"Beura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0395-4988","authenticated-orcid":false,"given":"Samira M.","family":"Azarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-198X","authenticated-orcid":false,"given":"Satish","family":"Ramadhyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9760-0288","authenticated-orcid":false,"given":"Yoji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"24132_CR1","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang, Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125, 3335\u20133337 (2015).","journal-title":"J. Clin. Invest."},{"key":"24132_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-med-112311-083918","volume":"64","author":"G Lizee","year":"2013","unstructured":"Lizee, G. et al. Harnessing the power of the immune system to target cancer. Annu. Rev. Med. 64, 71\u201390 (2013).","journal-title":"Annu. Rev. Med."},{"key":"24132_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581\u2013598 (2018).","journal-title":"Cancer Cell"},{"key":"24132_CR4","doi-asserted-by":"crossref","unstructured":"Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 10, eaat7807 (2018).","DOI":"10.1126\/scitranslmed.aat7807"},{"key":"24132_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","volume":"41","author":"JM Schenkel","year":"2014","unstructured":"Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41, 886\u2013897 (2014).","journal-title":"Immunity"},{"key":"24132_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2016.11.011","volume":"22","author":"PC Rosato","year":"2017","unstructured":"Rosato, P. C., Beura, L. K. & Masopust, D. Tissue resident memory T cells and viral immunity. Curr. Opin. Virol. 22, 44\u201350 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"24132_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","volume":"6","author":"F Mami-Chouaib","year":"2018","unstructured":"Mami-Chouaib, F. et al. Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer 6, 87 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"24132_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust, D., & Soerens, A. G. Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol. 37, 521\u2013546 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"24132_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nri2251","volume":"8","author":"JT Harty","year":"2008","unstructured":"Harty, J. T. & Badovinac, V. P. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 8, 107\u2013119 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"24132_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"24132_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nprot.2014.005","volume":"9","author":"KG Anderson","year":"2014","unstructured":"Anderson, K. G. et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat. Protoc. 9, 209\u2013222 (2014).","journal-title":"Nat. Protoc."},{"key":"24132_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cell.2015.03.031","volume":"161","author":"EM Steinert","year":"2015","unstructured":"Steinert, E. M. et al. Quantifying memory CD8 T cells reveals regionalization of immunosurveillance. Cell 161, 737\u2013749 (2015).","journal-title":"Cell"},{"key":"24132_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/ni.2568","volume":"14","author":"JM Schenkel","year":"2013","unstructured":"Schenkel, J. M., Fraser, K. A., Vezys, V. & Masopust, D. Sensing and alarm function of resident memory CD8(+) T cells. Nat. Immunol. 14, 509\u2013513 (2013).","journal-title":"Nat. Immunol."},{"key":"24132_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni.1718","volume":"10","author":"T Gebhardt","year":"2009","unstructured":"Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524\u2013530 (2009).","journal-title":"Nat. Immunol."},{"key":"24132_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature10851","volume":"483","author":"X Jiang","year":"2012","unstructured":"Jiang, X. et al. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 483, 227\u2013231 (2012).","journal-title":"Nature"},{"key":"24132_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).","journal-title":"Nat. Commun."},{"key":"24132_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986\u2013993 (2018).","journal-title":"Nat. Med."},{"key":"24132_CR18","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","volume":"194","author":"F Djenidi","year":"2015","unstructured":"Djenidi, F. et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J. Immunol. 194, 3475\u20133486 (2015).","journal-title":"J. Immunol."},{"key":"24132_CR19","doi-asserted-by":"crossref","unstructured":"Malik, B. T. et al. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci. Immunol. 2, eaam6346 (2017).","DOI":"10.1126\/sciimmunol.aam6346"},{"key":"24132_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-018-0812-9","volume":"565","author":"SL Park","year":"2019","unstructured":"Park, S. L. et al. Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. Nature 565, 366\u2013371 (2019).","journal-title":"Nature"},{"key":"24132_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16073","volume":"8","author":"M Enamorado","year":"2017","unstructured":"Enamorado, M. et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells. Nat. Commun. 8, 16073 (2017).","journal-title":"Nat. Commun."},{"key":"24132_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173\u2013200 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"24132_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.smim.2015.11.002","volume":"28","author":"YC Lu","year":"2016","unstructured":"Lu, Y. C. & Robbins, P. F. Cancer immunotherapy targeting neoantigens. Semin Immunol. 28, 22\u201327 (2016).","journal-title":"Semin Immunol."},{"key":"24132_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrc.2016.154","volume":"17","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Johnson, B. A. 3rd, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209\u2013222 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"24132_CR25","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"24132_CR26","first-page":"15","volume":"21","author":"A Sharma","year":"2019","unstructured":"Sharma, A., Suleyman, N., Jones, O. & Vasdev, N. Immunotherapy in urological tumors. Rev. Urol. 21, 15\u201320 (2019).","journal-title":"Rev. Urol."},{"key":"24132_CR27","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","volume":"10","author":"FE Gonzalez","year":"2014","unstructured":"Gonzalez, F. E. et al. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum. Vaccin Immunother. 10, 3261\u20133269 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"24132_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","volume":"17","author":"O Kepp","year":"2020","unstructured":"Kepp, O., Marabelle, A., Zitvogel, L. & Kroemer, G. Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. Nat. Rev. Clin. Oncol. 17, 49\u201364 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"24132_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le, D. T., Pardoll, D. M. & Jaffee, E. M. Cellular vaccine approaches. Cancer J. 16, 304\u2013310 (2010).","journal-title":"Cancer J."},{"key":"24132_CR30","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J. D. & Kohrt, H. E. In-situ tumor vaccination: bringing the fight to the tumor. Hum. Vaccin Immunother. 11, 1901\u20131909 (2015).","journal-title":"Hum. Vaccin Immunother."},{"key":"24132_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2741\/4487","volume":"22","author":"Y Keisari","year":"2017","unstructured":"Keisari, Y. Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. Front. Biosci. 22, 310\u2013347 (2017).","journal-title":"Front. Biosci."},{"key":"24132_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","volume":"14","author":"KF Chu","year":"2014","unstructured":"Chu, K. F. & Dupuy, D. E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14, 199\u2013208 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"24132_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.1200563","volume":"189","author":"A Gupta","year":"2012","unstructured":"Gupta, A. et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189, 558\u2013566 (2012).","journal-title":"J. Immunol."},{"key":"24132_CR34","first-page":"3325","volume":"57","author":"BA Foster","year":"1997","unstructured":"Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325\u20133330 (1997).","journal-title":"Cancer Res."},{"key":"24132_CR35","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/0008-5472.CAN-11-1782","volume":"72","author":"R Waitz","year":"2012","unstructured":"Waitz, R. et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72, 430\u2013439 (2012).","journal-title":"Cancer Res."},{"key":"24132_CR36","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1073\/pnas.0712269105","volume":"105","author":"M Fasso","year":"2008","unstructured":"Fasso, M. et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)\/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc. Natl Acad. Sci. USA 105, 3509\u20133514 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24132_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1109\/TBME.2014.2367543","volume":"62","author":"C Jiang","year":"2015","unstructured":"Jiang, C., Davalos, R. V. & Bischof, J. C. A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans. Biomed. Eng. 62, 4\u201320 (2015).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"24132_CR38","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10439-014-1133-2","volume":"43","author":"C Jiang","year":"2015","unstructured":"Jiang, C., Shao, Q. & Bischof, J. Pulse timing during irreversible electroporation achieves enhanced destruction in a hindlimb model of cancer. Ann. Biomed. Eng. 43, 887\u2013895 (2015).","journal-title":"Ann. Biomed. Eng."},{"key":"24132_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.2020192190","volume":"295","author":"B Geboers","year":"2020","unstructured":"Geboers, B. et al. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology 295, 254\u2013272 (2020).","journal-title":"Radiology"},{"key":"24132_CR40","doi-asserted-by":"publisher","first-page":"e0215093","DOI":"10.1371\/journal.pone.0215093","volume":"14","author":"E Guenther","year":"2019","unstructured":"Guenther, E. et al. Prostate cancer treatment with irreversible electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS ONE 14, e0215093 (2019).","journal-title":"PLoS ONE"},{"key":"24132_CR41","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","volume":"168","author":"C O\u2019Neill","year":"2020","unstructured":"O\u2019Neill, C. et al. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery 168, 610\u2013616 (2020).","journal-title":"Surgery"},{"key":"24132_CR42","doi-asserted-by":"publisher","first-page":"1652532","DOI":"10.1080\/2162402X.2019.1652532","volume":"8","author":"HJ Scheffer","year":"2019","unstructured":"Scheffer, H. J. et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology 8, 1652532 (2019).","journal-title":"Oncoimmunology"},{"key":"24132_CR43","first-page":"e4994","volume":"11","author":"A Tameez Ud Din","year":"2019","unstructured":"Tameez Ud Din, A., Tameez-Ud-Din, A., Chaudhary, F. M. D., Chaudhary, N. A. & Siddiqui, K. H. Irreversible electroporation for liver tumors: a review of literature. Cureus 11, e4994 (2019).","journal-title":"Cureus"},{"key":"24132_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-015-0571-1","volume":"17","author":"G Narayanan","year":"2016","unstructured":"Narayanan, G. & Doshi, M. H. Irreversible electroporation (IRE) in renal tumors. Curr. Urol. Rep. 17, 15 (2016).","journal-title":"Curr. Urol. Rep."},{"key":"24132_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.001","volume":"503","author":"Z Dai","year":"2021","unstructured":"Dai, Z. et al. Irreversible electroporation induces CD8(+) T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Lett. 503, 1\u201310 (2021).","journal-title":"Cancer Lett."},{"key":"24132_CR46","doi-asserted-by":"publisher","first-page":"e48749","DOI":"10.1371\/journal.pone.0048749","volume":"7","author":"X Li","year":"2012","unstructured":"Li, X. et al. Immunologic response to tumor ablation with irreversible electroporation. PLoS ONE 7, e48749 (2012).","journal-title":"PLoS ONE"},{"key":"24132_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1148\/radiol.2015151166","volume":"280","author":"BE Bulvik","year":"2016","unstructured":"Bulvik, B. E. et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology 280, 413\u2013424 (2016).","journal-title":"Radiology"},{"key":"24132_CR48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1245\/s10434-018-07144-3","volume":"26","author":"H Pandit","year":"2019","unstructured":"Pandit, H. et al. Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma. Ann. Surg. Oncol. 26, 800\u2013806 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"24132_CR49","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.jvir.2018.07.009","volume":"29","author":"SB White","year":"2018","unstructured":"White, S. B., Zhang, Z., Chen, J., Gogineni, V. R. & Larson, A. C. Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer. J. Vasc. Inter. Radio. 29, 1764\u20131769 (2018).","journal-title":"J. Vasc. Inter. Radio."},{"key":"24132_CR50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.surg.2013.06.005","volume":"154","author":"JT Au","year":"2013","unstructured":"Au, J. T. et al. Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response. Surgery 154, 496\u2013503 (2013).","journal-title":"Surgery"},{"key":"24132_CR51","doi-asserted-by":"crossref","unstructured":"Go, E. J. et al. Combination of irreversible electroporation and STING agonist for effective cancer immunotherapy. Cancers 12, 3123 (2020).","DOI":"10.3390\/cancers12113123"},{"key":"24132_CR52","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1158\/2326-6066.CIR-19-0101","volume":"7","author":"JSS Narayanan","year":"2019","unstructured":"Narayanan, J. S. S. et al. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model. Cancer Immunol. Res. 7, 1714\u20131726 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"24132_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08782-1","volume":"10","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat. Commun. 10, 899 (2019).","journal-title":"Nat. Commun."},{"key":"24132_CR54","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/jso.24404","volume":"114","author":"RC Martin 2nd","year":"2016","unstructured":"Martin, R. C. 2nd et al. Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J. Surg. Oncol. 114, 865\u2013871 (2016).","journal-title":"J. Surg. Oncol."},{"key":"24132_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/02656736.2018.1539253","volume":"36","author":"Q Shao","year":"2019","unstructured":"Shao, Q. et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int. J. Hyperth. 36, 130\u2013138 (2019).","journal-title":"Int. J. Hyperth."},{"key":"24132_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2008.04.010","volume":"28","author":"JJ Obar","year":"2008","unstructured":"Obar, J. J., Khanna, K. M. & Lefrancois, L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28, 859\u2013869 (2008).","journal-title":"Immunity"},{"key":"24132_CR57","doi-asserted-by":"publisher","first-page":"e1043504","DOI":"10.1080\/2162402X.2015.1043504","volume":"4","author":"HI Cho","year":"2015","unstructured":"Cho, H. I., Jung, S. H., Sohn, H. J., Celis, E. & Kim, T. G. An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects. Oncoimmunology 4, e1043504 (2015).","journal-title":"Oncoimmunology"},{"key":"24132_CR58","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.4049\/jimmunol.1102604","volume":"188","author":"M Zhang","year":"2012","unstructured":"Zhang, M. et al. Augmented IL-15Ralpha expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J. Immunol. 188, 6156\u20136164 (2012).","journal-title":"J. Immunol."},{"key":"24132_CR59","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"24132_CR60","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3389\/fimmu.2019.01392","volume":"10","author":"A Garcia-Garijo","year":"2019","unstructured":"Garcia-Garijo, A., Fajardo, C. A. & Gros, A. Determinants for neoantigen identification. Front. Immunol. 10, 1392 (2019).","journal-title":"Front. Immunol."},{"key":"24132_CR61","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.4049\/jimmunol.177.10.6705","volume":"177","author":"K Kedzierska","year":"2006","unstructured":"Kedzierska, K. et al. Quantification of repertoire diversity of influenza-specific epitopes with predominant public or private TCR usage. J. Immunol. 177, 6705\u20136712 (2006).","journal-title":"J. Immunol."},{"key":"24132_CR62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3905","volume":"15","author":"DC Tscharke","year":"2015","unstructured":"Tscharke, D. C., Croft, N. P., Doherty, P. C. & La Gruta, N. L. Sizing up the key determinants of the CD8(+) T cell response. Nat. Rev. Immunol. 15, 705\u2013716 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"24132_CR63","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.4049\/jimmunol.172.8.4875","volume":"172","author":"D Masopust","year":"2004","unstructured":"Masopust, D. et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J. Immunol. 172, 4875\u20134882 (2004).","journal-title":"J. Immunol."},{"key":"24132_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12464-3","volume":"10","author":"PA Szabo","year":"2019","unstructured":"Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. Nat. Commun. 10, 4706 (2019).","journal-title":"Nat. Commun."},{"key":"24132_CR65","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1073\/pnas.1810326116","volume":"116","author":"CE Nelson","year":"2019","unstructured":"Nelson, C. E. et al. Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. Proc. Natl Acad. Sci. USA 116, 2640\u20132645 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24132_CR66","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1016\/j.celrep.2019.08.038","volume":"28","author":"CE Nelson","year":"2019","unstructured":"Nelson, C. E. et al. Robust iterative stimulation with self-antigens overcomes CD8(+) T cell tolerance to self- and tumor antigens. Cell Rep. 28, 3092\u20133104.e3095 (2019).","journal-title":"Cell Rep."},{"key":"24132_CR67","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1073\/pnas.1203479109","volume":"109","author":"P Yu","year":"2012","unstructured":"Yu, P. et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA 109, 6187\u20136192 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24132_CR68","doi-asserted-by":"crossref","unstructured":"Hopkins, A. C. et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight 3, e122092 (2018).","DOI":"10.1172\/jci.insight.122092"},{"key":"24132_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","volume":"38","author":"KC Soares","year":"2015","unstructured":"Soares, K. C. et al. PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 38, 1\u201311 (2015).","journal-title":"J. Immunother."},{"key":"24132_CR70","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le, D. T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382\u2013389 (2013).","journal-title":"J. Immunother."},{"key":"24132_CR71","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/imt-2019-0019","volume":"11","author":"VG Patel","year":"2019","unstructured":"Patel, V. G. & Oh, W. K. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy 11, 903\u2013912 (2019).","journal-title":"Immunotherapy"},{"key":"24132_CR72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551\u2013555 (2017).","journal-title":"Nat. Med."},{"key":"24132_CR73","doi-asserted-by":"crossref","unstructured":"Subudhi, S. K. et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 12, eaaz3577 (2020).","DOI":"10.1126\/scitranslmed.aaz3577"},{"key":"24132_CR74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"24132_CR75","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"24132_CR76","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"24132_CR77","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1172\/JCI120775","volume":"128","author":"A Popovic","year":"2018","unstructured":"Popovic, A., Jaffee, E. M. & Zaidi, N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J. Clin. Invest. 128, 3209\u20133218 (2018).","journal-title":"J. Clin. Invest."},{"key":"24132_CR78","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf, D. et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J. Clin. Oncol. 35, 3807\u20133814 (2017).","journal-title":"J. Clin. Oncol."},{"key":"24132_CR79","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buque, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"24132_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.critrevonc.2017.03.003","volume":"113","author":"A Sindoni","year":"2017","unstructured":"Sindoni, A., Minutoli, F., Ascenti, G. & Pergolizzi, S. Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature. Crit. Rev. Oncol. Hematol. 113, 63\u201370 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"24132_CR81","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","volume":"9","author":"Y Yan","year":"2018","unstructured":"Yan, Y. et al. Combining immune checkpoint inhibitors with conventional cancer therapy. Front. Immunol. 9, 1739 (2018).","journal-title":"Front. Immunol."},{"key":"24132_CR82","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557\u2013569 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"24132_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12319-x","volume":"10","author":"E Menares","year":"2019","unstructured":"Menares, E. et al. Tissue-resident memory CD8(+) T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat. Commun. 10, 4401 (2019).","journal-title":"Nat. Commun."},{"key":"24132_CR84","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4049\/jimmunol.1300652","volume":"191","author":"MY Gerner","year":"2013","unstructured":"Gerner, M. Y., Heltemes-Harris, L. M., Fife, B. T. & Mescher, M. F. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191, 1011\u20131015 (2013).","journal-title":"J. Immunol."},{"key":"24132_CR85","first-page":"2281","volume":"40","author":"IR Hart","year":"1980","unstructured":"Hart, I. R. & Fidler, I. J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281\u20132287 (1980).","journal-title":"Cancer Res."},{"key":"24132_CR86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.immuni.2018.01.015","volume":"48","author":"LK Beura","year":"2018","unstructured":"Beura, L. K. et al. T cells in nonlymphoid tissues give rise to lymph-node-resident memory T cells. Immunity 48, 327\u2013338.e325 (2018).","journal-title":"Immunity"},{"key":"24132_CR87","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.4049\/jimmunol.1201682","volume":"189","author":"KG Anderson","year":"2012","unstructured":"Anderson, K. G. et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. J. Immunol. 189, 2702\u20132706 (2012).","journal-title":"J. Immunol."},{"key":"24132_CR88","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.4049\/jimmunol.1200402","volume":"188","author":"KA Casey","year":"2012","unstructured":"Casey, K. A. et al. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J. Immunol. 188, 4866\u20134875 (2012).","journal-title":"J. Immunol."},{"key":"24132_CR89","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.274.5284.94","volume":"274","author":"JD Altman","year":"1996","unstructured":"Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94\u201396 (1996).","journal-title":"Science"},{"key":"24132_CR90","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.4049\/jimmunol.1501805","volume":"197","author":"JK Fiege","year":"2016","unstructured":"Fiege, J. K., Beura, L. K., Burbach, B. J. & Shimizu, Y. Adhesion- and degranulation-promoting adapter protein promotes CD8 T cell differentiation and resident memory formation and function during an acute infection. J. Immunol. 197, 2079\u20132089 (2016).","journal-title":"J. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24132-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24132-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:01:27Z","timestamp":1669986087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24132-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24132"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24132-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.F. is employed by Boston Scientific. S.R. retired from BTG plc in 2018. Both B.F. and S.R. provided conceptual and technical oversight to portions of the project. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3862"}}